Prognostic and predictive value of extended RAS mutation and mismatch repair status in stage III colorectal cancer

Abstract

The prognostic and predictive value of KRAS gene mutations in stage III colorectal cancer is controversial because many recent clinical trials have not involved a surgery-alone arm.　Additionally, data on the significance of extended RAS (KRAS/NRAS) mutations in stage　III cancer are not available. Hence, we performed a combined analysis of two phase 3　randomized trials, in which the usefulness of adjuvant chemotherapy with UFT was　evaluated, as compared with surgery alone. We determined the association of extended　RAS and mismatch repair (MMR) status with the effectiveness of adjuvant chemotherapy.　Mutations in KRAS exons 2, 3, 4 and NRAS exons 2, 3 were detected by direct DNA　sequencing. Tumor MMR status was determined by immunohistochemistry. Total RAS mutations were detected in 134/304 (44%) patients. In patients with RAS mutations, a significant benefit was associated with adjuvant UFT in RFS (HR=0.49 (0.27-0.91); p=0.02) and OS (HR=0.51 (0.26-0.97); p=0.03). In contrast, among patients without RAS mutations, there was no difference in RFS and OS between the adjuvant UFT group and surgery-alone group. MMR deficiency (dMMR) was detected in 23/304 (8%) patients. MMR status was neither prognostic nor predictive for adjuvant chemotherapy, although the small number of dMMR tumors might have affected. An interaction analysis showed that there was a better RFS among patients treated with UFT with RAS mutations, but not for those without RAS mutations. Extended RAS (KRAS/NRAS) mutations are proposed be predictive indicators with respect to the efficacy of adjuvant UFT chemotherapy in patients with resected stage III colorectal cancer.

This article is protected by copyright. All rights reserved.

from Cancer via ola Kala on Inoreader http://ift.tt/1pbqkHH
via IFTTT